[go: up one dir, main page]

WO2001075058A2 - Nouveau polypeptide, aminoacyl-arnt synthetase humaine 15 de type ii, et polynucleotide codant pour ce polypeptide - Google Patents

Nouveau polypeptide, aminoacyl-arnt synthetase humaine 15 de type ii, et polynucleotide codant pour ce polypeptide Download PDF

Info

Publication number
WO2001075058A2
WO2001075058A2 PCT/CN2001/000525 CN0100525W WO0175058A2 WO 2001075058 A2 WO2001075058 A2 WO 2001075058A2 CN 0100525 W CN0100525 W CN 0100525W WO 0175058 A2 WO0175058 A2 WO 0175058A2
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
aminoacyl
polynucleotide
trna synthetase
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2001/000525
Other languages
English (en)
Chinese (zh)
Other versions
WO2001075058A3 (fr
Inventor
Yumin Mao
Yi Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Biowindow Gene Development Inc
Original Assignee
Shanghai Biowindow Gene Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Biowindow Gene Development Inc filed Critical Shanghai Biowindow Gene Development Inc
Priority to AU60032/01A priority Critical patent/AU6003201A/en
Publication of WO2001075058A2 publication Critical patent/WO2001075058A2/fr
Publication of WO2001075058A3 publication Critical patent/WO2001075058A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • a “humanized antibody” refers to an antibody in which the amino acid sequence of a non-antigen binding region is replaced to become more similar to a human antibody, but still retains the original binding activity.
  • the polynucleotide of the present invention may be in the form of DNA or RNA.
  • DNA forms include cDNA, genomic DNA, or synthetic DM.
  • DNA can be single-stranded or double-stranded.
  • DNA can be coding or non-coding.
  • the coding region sequence encoding a mature polypeptide may be the same as the coding region sequence shown in SEQ ID NO: 1 or a degenerate variant.
  • a "degenerate variant" refers to a nucleic acid sequence encoding a protein or polypeptide having SEQ ID NO: 2 but having a sequence different from the coding region sequence shown in SEQ ID NO: 1 in the present invention.
  • polypeptides or fragments thereof of the present invention can also be used to treat or prevent diseases caused by nervous system dysfunction, including but not limited to: myasthenia gravis, spinal muscular atrophy, myo-pseudohypertrophy, ankylosal muscular dystrophy, Dystonia, retarded movement, etc.
  • Polynucleotides encoding human class II aminoacyl-tRNA synthetase 15 can also be used for a variety of therapeutic purposes.
  • Gene therapy technology can be used to treat abnormal cell proliferation, development, or metabolism caused by non-expression or abnormal / non-active expression of a population of aminoacyl-tRNA synthetase 15.
  • Recombinant gene therapy vectors (such as viral vectors) can be designed to express variant populations of aminoacyl-t RNA synthetase 15 to inhibit endogenous human aminoacyl-t RNA synthetase 15 activity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un nouveau polypeptide, une aminoacyl-ARNt synthétase humaine 15 de type II, et un polynucléotide codant pour ce polypeptide ainsi qu'un procédé d'obtention de ce polypeptide par des techniques recombinantes d'ADN. L'invention concerne en outre les applications de ce polypeptide dans le traitement de maladies, notamment des tumeurs malignes, de l'hémopathie, des troubles du développement, de l'infection par VIH, de maladies immunitaires et de diverses inflammations. L'invention concerne aussi l'antagoniste agissant contre le polypeptide et son action thérapeutique ainsi que les applications de ce polynucléotide codant pour l'aminoacyl-ARNt synthétase humaine 15 de type II.
PCT/CN2001/000525 2000-03-29 2001-03-26 Nouveau polypeptide, aminoacyl-arnt synthetase humaine 15 de type ii, et polynucleotide codant pour ce polypeptide Ceased WO2001075058A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60032/01A AU6003201A (en) 2000-03-29 2001-03-26 A novel polypeptide, human aminoacyl-trna synthetase 15 type ii and the polynucleotide encoding the polypeptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN00115294.7 2000-03-29
CN00115294A CN1315512A (zh) 2000-03-29 2000-03-29 一种新的多肽——人II类氨酰基－tRNA合成酶15和编码这种多肽的多核苷酸

Publications (2)

Publication Number Publication Date
WO2001075058A2 true WO2001075058A2 (fr) 2001-10-11
WO2001075058A3 WO2001075058A3 (fr) 2002-02-07

Family

ID=4584762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2001/000525 Ceased WO2001075058A2 (fr) 2000-03-29 2001-03-26 Nouveau polypeptide, aminoacyl-arnt synthetase humaine 15 de type ii, et polynucleotide codant pour ce polypeptide

Country Status (3)

Country Link
CN (1) CN1315512A (fr)
AU (1) AU6003201A (fr)
WO (1) WO2001075058A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111849929B (zh) 2019-04-30 2021-05-11 苏州鲲鹏生物技术有限公司 高效引入赖氨酸衍生物的氨酰基—tRNA合成酶

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798240A (en) * 1994-09-13 1998-08-25 Cubist Pharmaceuticals, Inc. Recombinant mycobacterial methionyl-tRNA synthetase genes and methods of use therefore

Also Published As

Publication number Publication date
CN1315512A (zh) 2001-10-03
WO2001075058A3 (fr) 2002-02-07
AU6003201A (en) 2001-10-15

Similar Documents

Publication Publication Date Title
WO2001094568A1 (fr) Nouveau polypeptide, aminoacyl-arnt synthetase humaine 10 de type ii, et polynucleotide codant ce polypeptide
WO2001075058A2 (fr) Nouveau polypeptide, aminoacyl-arnt synthetase humaine 15 de type ii, et polynucleotide codant pour ce polypeptide
WO2001068689A1 (fr) Nouveau polypeptide, 1alpha sous-unite 13 humaine du facteur adaptatif de l'hypoxie, et polynucleotide codant pour ce polypeptide
WO2001083538A1 (fr) Nouveau polypeptide, proteine humaine 36 du gene k-ras, et polynucleotide codant pour ce polypeptide
WO2001040487A1 (fr) NOUVEAU POLYPEPTIDE, SYNTHASE HUMAINE 9 DE TYPE II A BASE AMINEE D'ARNt, ET POLYNUCLEOTIDE CODANT POUR CE POLYPEPTIDE
WO2001072807A1 (fr) Nouveau polypeptide, neuropeptide humain 11, et polynucleotide codant pour ce polypeptide
WO2001079423A2 (fr) Nouveau polypeptide, proteine humaine bcr 10, et polynucleotide codant pour ce polypeptide
WO2001055414A1 (fr) Nouveau polypeptide, proteine rgs 17, et polynucleotide codant pour ce polypeptide
WO2001075054A2 (fr) Nouveau polypeptide, facteur humain de regulation 30 de la transcription de la microglobuline, et polynucleotide codant pour ce polypeptide
WO2001046430A1 (fr) Nouveau polypeptide, peroxydase 12, et polynucleotide codant pour ce polypeptide
WO2001055399A1 (fr) Nouveau polypeptide, dipeptide aminopeptidase humaine 28, et polynucleotide codant pour ce polypeptide
WO2001066575A1 (fr) Nouveau polypeptide, actine 49, et polynucleotide codant pour ce polypeptide
WO2001066578A1 (fr) Nouveau polypeptide, adn polymerase 10, et polynucleotide codant pour ce polypeptide
WO2001074883A1 (fr) Nouveau polypeptide, proteine endoase humaine 11, et polynucleotide codant pour ce polypeptide
WO2001092323A1 (fr) Nouveau polypeptide, aminoacyl-arnt synthetase humaine 17 de type ii, et polynucleotide codant ce polypeptide
WO2001055415A1 (fr) Nouveau polypeptide, aminoacyl-arnt synthetase humaine de type ii 75, et polynucleotide codant pour ce polypeptide
WO2002020744A1 (fr) Nouveau polypeptide, c1p protease humaine 23.32, et polynucleotide codant ce polypeptide
WO2001075029A2 (fr) Nouveau polypeptide, facteur humain 11 associe a nf-e2, et polynucleotide codant pour ce polypeptide
WO2001066588A1 (fr) Nouveau polypeptide, facteur humain 1-12 de liaison intensive de leucocytes, et polynucleotide codant pour ce polypeptide
WO2001055373A1 (fr) Nouveau polypeptide, capside proteine vp4, 13, et polynucleotide codant pour ce polypeptide
WO2001075024A2 (fr) Nouveau polypeptide, facteur humain 13 associe a nf-e2, et polynucleotide codant pour ce polypeptide
WO2002026952A1 (fr) Nouveau polypeptide, serine/threonine proteine kinase humaine 11.22, et polynucleotide codant ce polypeptide
WO2001077165A1 (fr) Nouveau polypeptide, proteine humaine de liaison 12 d'une proteine precurseur de l'amyloide, et polynucleotide codant pour ce polypeptide
WO2001070983A1 (fr) Nouveau polypeptide, proteine antigene prostatique specifique membranaire 9, et polynucleotide codant pour ce polypeptide
WO2001079431A2 (fr) Nouveau polypeptide, proteine humaine d'interaction 15 avec la proteine huntingtine, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP